Enzalutamide in prostate cancer after chemotherapy

New England Journal of Medicine

Volumn 367, Issue 25, 2012, Pages 2448-2449

  Berruti, Alfredo ^a   Generali, Daniele ^b   Tampellini, Marco ^c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CREMONA HOSPITAL   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN; ENZALUTAMIDE; GLUCOCORTICOID; PLACEBO; PREDNISONE;

CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; EPILEPSY; HEADACHE; HUMAN; LETTER; MIGRAINE; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84871306277     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1212940     Document Type: Letter

References (5)

1. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
2. MacGregor EA. Perimenopausal migraine in women with vasomotor symptoms. Maturitas 2012;71:79-82.
3. Rogawski MA. Common pathophysiologic mechanisms in migraine and epilepsy. Arch Neurol 2008;65:709-14. (Pubitemid 351831448)
4. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
5. Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ 2008;336:1359-61. (Pubitemid 351916691)